Over the last 12 months, we have made significant progress against our 2025 Patient Access Targets, which are linked to a sustainability bond (SLB) issued in September 2020. Making innovation accessible and affordable in low-income settings The Access to Medicines Index has repeatedly recognized our efforts, ranking Novartis 2nd in the 2021 index and highlighting Novartis as the only company with equitable access strategies in low-income countries across its portfolio. Guided by the Novartis Access Principles and taking local economic realities into account, Novartis applies a broad range of approaches to ensure medicines can be available where they are needed, including tiered pricing, innovative business models and emerging market brand strategies. The WHO estimates that more than 2 billion people worldwide lack access to basic medicines. “Looking ahead, we are renewing our focus on our ESG material topics, redoubling our efforts on improving access to medicines and accelerating our journey toward a zero-carbon future.”Īccess to medicines remains one of the world’s biggest healthcare challenges, and as confirmed by the recent Novartis materiality assessment, it remains one of the most material ESG topics for the company. Coupled with our inspired, curious and unbossed culture, we believe ESG efforts on our most material topics will help drive our overall performance as a company and deliver long-term value for our stakeholders,” said Vas Narasimhan, CEO of Novartis. “ESG is central to the Novartis strategy and is critical to delivering on our purpose to reimagine medicine to improve and extend people’s lives. Committed to achieving net zero carbon emissions across our value chain by 2040īasel, SeptemAt its eighth annual ESG investor event hosted today, Novartis shared progress against its Environmental, Social and Governance (ESG) targets and updated on its most material ESG topics, including access to medicines, patient health and safety, innovation and ethical standards.Continued our global health leadership with positive phase 2b results for our next generation antimalarial therapy ganaplacide in combination with lumefantrine which support its continued development.Announced a planned 10-year commitment with historically black colleges and universities to address root causes of systemic disparities in health outcomes. Reached nearly 29 million patients to date in 2021 through our flagship programs and strategic innovative brands.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |